Very late antigen (VLA) expression by normal and neoplastic human plasma cells; including an assessment of antibodies submitted to the Vth international workshop on leucocyte differentiation antigens using human myeloma cell lines

Leukemia Research

Volumn 20, Issue 7, 1996, Pages 619-624

  Drew, Marion ^a   Barker, Helen F ^a   Ball, Jennifer ^a   Pearson, Charles ^b   Cook, G ^b   Franklin, Ian ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adhesion molecules; Beta 1 integrins; Myeloma; VLA (CD29 CD49)

Indexed keywords

ANTIBODY; BETA1 INTEGRIN; DIFFERENTIATION ANTIGEN; FIBRONECTIN; HERMES ANTIGEN; LEUKOCYTE ANTIGEN; VERY LATE ACTIVATION ANTIGEN;

ANTIGEN ANTIBODY REACTION; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PATHOPHYSIOLOGY; PHENOTYPE; PLASMACYTOMA; PRIORITY JOURNAL; VENULE;

EID: 0030198620     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/0145-2126(95)00097-6     Document Type: Article

References (15)

1. 1. Barker H. M., Ball J., Drew M. & Franklin I. M. (1993) Multiple myeloma: the biology of malignant plasma cells. Blood Rev. 7, 19.
2. 2. Pigott R. & Power C. (1993) The Adhesion Molecule FactsBook. Academic Press, London.
3. 3. Modderman P. W. (1989) Cluster report: CDw49. In Leucocyte Typing IV. White Cell Differentiation Antigens (Knapp W., Dorken B., Gilks W., et al., Eds), p. 1020. Oxford University Press, Oxford.
4. 4. Modderman P. W. (1989) New clusters: CD29 / CDw49, CD47, CD51, CD55, and CD 61 and Cluster report: CD29. In Leucocyte Typing IV. White Cell Differentiation Antigens (Knapp W., Dorken B., Gilks W., et al., Eds), p. 1017. Oxford University Press, Oxford.
5. 5. Kawano M. M., Huang N., Harada H., et al. (1993) Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 82, 564.
6. 6. Hemler M. E. & Zutter M. M. (1993) β1 Integrins (CD29/ 49). Workshop session AS03. 5th International Conference on Human Leucocyte Differentiation Antigens. Tissue Antigens 42, 197.
7. 7. Hamilton M. S., Ball J., Bromidge E., Lowe J. & Franklin I. M. (1990) Characterisation of a new IgG lambda myeloma plasma cell line (EJM) - a further tool in the investigation of the biology of multiple myeloma. Br. J. Haematol. 75, 378.
8. 1-κ plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B-cell stimulatory factor 2. Clin. Exp. Immunol. 75, 93.
9. 9. Barker H. F., Hamilton M. S., Ball J., Drew M. & Franklin I. M. (1991) Differential expression of the bcl-2 protooncogene by four clones of a new myeloma cell line. In Monoclonal Gammapathies III - Clinical Significance and Basic Mechanisms (Radl J. & van Camp B., Eds), p. 155. Eurage, Brussels.
10. 10. Nilsson K., Bennich H., Johansson S. G. O. & Ponten J. (1970) Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7, 477.
11. 11. Matsuoka Y., Moore G. E., Yaig Y. & Pressman D. (1967) Production of free light chains of immunoglobulin by a haemopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. 125, 1246.
12. 12. Hamilton M. S., Ball J., Bromidge E. & Franklin I. M. (1991) The surface antigen expression of human neoplastic plasma cells includes molecules involved in lymphocyte recirculation and adhesion. Br. J. Haematol. 78, 60.
13. 13. Barker H. F., Ball J., Drew M. & Franklin I. M. (1992) Expression of ICAM-1, H-CAM and other adhesion molecules is increased in human myeloma cell lines after contact with marrow stroma. Blood 80, (Suppl. 1) 360a.
14. 14. Hulzman B., McIntyre B. N. & Weissman I. L. (1989) Identification of a murine Peyer's patch - specific lymphocyte homing receptor as an integrin molecule with an α chain homologous to human VLA-4a. Cell 56, 37.
15. 15. Jalkenen S., Bargatze R. F., de los Toyos J. & Butcher E. C. (1987) Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal or synovial endothelial cells. J. Cell Biol. 105, 983.